Loading...
•
Jun 30, 2020
West Pharma Q2 2020 Earnings Report
Announced second-quarter 2020 financial results, reflecting business strength and resilience.
Key Takeaways
West Pharmaceutical Services reported a 12.2% increase in net sales to $527.2 million and a 40% increase in adjusted-diluted EPS to $1.25 for the second quarter of 2020. The company is raising full-year 2020 net sales guidance to between $2.035 billion and $2.055 billion, and adjusted-diluted EPS guidance to between $4.15 and $4.25.
Net sales grew by 12.2% to $527.2 million, with organic sales growth of 14.3%.
Reported-diluted EPS increased by 38% to $1.21.
Adjusted-diluted EPS increased by 40% to $1.25.
Full-year 2020 net sales guidance raised to a new range of between $2.035 billion and $2.055 billion.
West Pharma
West Pharma
West Pharma Revenue by Segment
Revenue by Segment
Proprietary Products Revenue
CapyFin.comContract-Manufactured Products Revenue
CapyFin.com Forward Guidance
Full-year 2020 net sales are expected to be in a range of between $2.035 billion and $2.055 billion. Organic sales growth is expected to be approximately 12%. Full-year 2020 adjusted-diluted EPS is expected to be in a range of between $4.15 and $4.25.
Positive Outlook
- Full-year 2020 net sales guidance is expected to be in a range of between $2.035 billion and $2.055 billion.
- Organic sales growth is expected to be approximately 12%.
- Net sales guidance includes an estimated full-year headwind of $26 million for the full-year 2020 based on current foreign exchange rates.
- Full-year 2020 adjusted-diluted EPS is expected to be in a range of between $4.15 and $4.25.
- Full-year adjusted-diluted EPS guidance includes an estimated headwind of approximately $0.07 based on current foreign currency exchange rates.
Challenges Ahead
- The revised guidance includes a $0.16 EPS impact from tax benefits from stock-based compensation in the first six months of 2020.
- For the remainder of the year, our EPS guidance range assumes a tax rate of 24% and does not include potential tax benefits from stock-based compensation.
- Any tax benefits associated with stock-based compensation beyond those recorded in the first six months of 2020 would provide a positive adjustment to our full-year EPS guidance.
- The duration and severity of the global COVID-19 pandemic, including prevailing economic conditions and general uncertainties relating thereto that may be unknown and unforeseeable
- Customers’ changing inventory requirements and manufacturing plans and customer decisions to move forward with our new products and product categories, including any re-prioritization of product needs due to COVID-19
Revenue & Expenses
Visualization of income flow from segment revenue to net income